Natco Pharma Ka Dhamaka! Generic Semaglutide Launch Se Price War Shuru, Brand Se **90%** Tak Sasta

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorKavya Nair|Published at:
Natco Pharma Ka Dhamaka! Generic Semaglutide Launch Se Price War Shuru, Brand Se **90%** Tak Sasta
Overview

Arre bhaiyo aur behno, Natco Pharma ne ekdum dhamakedar move kiya hai! Jaise hi Novo Nordisk ka patent khatam hua, Natco ne apna generic Semaglutide, Semanat aur Semafull, launch kar diya hai. Aur price kya rakha hai? Sirf **₹1,290** se **₹1,750** per month! Matlab, brand wale drug se **90%** tak cheaper. Ab dekho asli price war shuru!

Natco Pharma ne yeh move February 2026 mein hi CDSCO se approval milne ke baad plan kar liya tha. Aur fir, March 21, 2026 ko, jaise hi Novo Nordisk ka patent expiry hua, unhone India mein apne generic Semaglutide products – Semanat aur Semafull – launch kar diye. Inki multidose vials ka price sirf ₹1,290 se ₹1,750 per month hai. Company ka daava hai ki yeh India mein sabse affordable GLP-1 therapy ban gayi hai, jo innovator se 70% tak aur original branded products se 90% tak sasti hai. Is launch ke baad March 20, 2026 ko company ka share price 2.48% badh kar ₹961.35 ho gaya tha.

Ab jab Novo Nordisk ka patent March 20, 2026 ko khatam ho gaya hai, toh lagta hai market mein floodgates khul gaye hain! 40 se zyada Indian drug makers ab 50 generic brands launch karne ko taiyar hain. Baaki companies ka price point around ₹3,000 se ₹5,000 per month ho sakta hai, lekin Natco ne toh ₹1,290-₹1,750 ka price set karke ek naya benchmark bana diya hai. Isse ek zabardast price war hone wali hai. India mein Type 2 diabetes aur obesity ka burden kaafi zyada hai, toh GLP-1 drugs ki demand bhi badh rahi hai. India mein GLP-1 receptor agonist market jo 2024 mein $82.2 million ka tha, woh 2030 tak $352.3 million tak pahunch sakta hai, yaani ki paanch guna tak badh sakta hai.

Ab valuation ki baat karein toh Natco Pharma ki market cap lagbhag ₹17,000 crore hai, aur P/E ratio 11x ke aas paas hai. Yeh apne competitors jaise Dr. Reddy's (market cap ₹106,000 crore, P/E 18.5x), Sun Pharma (market cap ₹427,000 crore, P/E 38.3x), aur Eris Lifesciences (market cap ₹17,700 crore, P/E 49x) ke comparison mein kaafi kam hai. Lagta hai investors Natco ke business model ko thoda alag nazar se dekh rahe hain. Lekin haan, yeh aggressive pricing strategy risk bhi laati hai. Price war se margins kam ho sakte hain aur sabhi companies ke liye profit maintain karna mushkil ho sakta hai. Experts keh rahe hain ki aane wale 2 se 3 saal mein sirf top 6 se 8 brands hi tik paayenge. Iske alawa, cold chain maintain karna aur delivery devices ki quality bhi bahut important hogi. Agar yeh sab manage nahi kiya toh regulatory scrutiny bhi badh sakti hai.

Disclaimer:This content is for informational purposes only and does not constitute financial or investment advice. Readers should consult a SEBI-registered advisor before making decisions. Investments are subject to market risks, and past performance does not guarantee future results. The publisher and authors are not liable for any losses. Accuracy and completeness are not guaranteed, and views expressed may not reflect the publication’s editorial stance.